Deep Vein Thrombosis

Cardiovascular
8
Pipeline Programs
7
Companies
8
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
4
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
APIXABANApproved
apixaban
Unknown Company
oral2020
U
RIVAROXABANApproved
rivaroxaban
Unknown Company
oral2025

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
2 programs
1
RivaroxabanPhase 3
RivaroxabanN/A
Genentech
GenentechCA - Oceanside
2 programs
2
Recombinant tissue plasminogen activatorPhase 31 trial
Recombinant tissue plasminogen activatorPhase 31 trial
Active Trials
NCT02767232Withdrawn0Est. Jun 2023
NCT00790335Completed692Est. Jan 2017
Pfizer
PfizerNEW YORK, NY
1 program
1
ApixabanPhase 31 trial
Active Trials
NCT01780987Completed80Est. Sep 2014
DS
Daiichi SankyoChina - Shanghai
2 programs
1
1
edoxaban tosylatePhase 21 trial
Edoxaban low dosePhase 11 trial
Active Trials
NCT02303431Completed66Est. Sep 2021
NCT01662908Completed85Est. Mar 2014
E
EisaiChina - Liaoning
1 program
3 Screen Electronic AlertN/A1 trial
Active Trials
NCT00550082Completed880Est. Nov 2009
Penumbra
PenumbraALAMEDA, CA
1 program
Indigo Aspiration SystemN/A1 trial
Active Trials
NCT05003843Active Not Recruiting229Est. Feb 2027
bioMerieux
bioMerieuxFrance - Marcy l'Étoile
1 program
Understanding Risk Factors Involved in Developing a Second Blood Clot.N/A1 trial
Active Trials
NCT00261014UnknownEst. Mar 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GenentechRecombinant tissue plasminogen activator
PfizerApixaban
GenentechRecombinant tissue plasminogen activator
Daiichi Sankyoedoxaban tosylate
Daiichi SankyoEdoxaban low dose
PenumbraIndigo Aspiration System
Eisai3 Screen Electronic Alert
bioMerieuxUnderstanding Risk Factors Involved in Developing a Second Blood Clot.

Clinical Trials (8)

Total enrollment: 2,032 patients across 8 trials

NCT02767232GenentechRecombinant tissue plasminogen activator

Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial

Start: Jul 2018Est. completion: Jun 20230
Phase 3Withdrawn
NCT01780987PfizerApixaban

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Start: Jan 2013Est. completion: Sep 201480 patients
Phase 3Completed
NCT00790335GenentechRecombinant tissue plasminogen activator

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Start: Nov 2009Est. completion: Jan 2017692 patients
Phase 3Completed
NCT01662908Daiichi Sankyoedoxaban tosylate

A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Start: Aug 2012Est. completion: Mar 201485 patients
Phase 2Completed
NCT02303431Daiichi SankyoEdoxaban low dose

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Start: Nov 2014Est. completion: Sep 202166 patients
Phase 1Completed
NCT05003843PenumbraIndigo Aspiration System

BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

Start: Sep 2021Est. completion: Feb 2027229 patients
N/AActive Not Recruiting
NCT00550082Eisai3 Screen Electronic Alert

3 Screen Electronic Alert

Start: Jul 2007Est. completion: Nov 2009880 patients
N/ACompleted
NCT00261014bioMerieuxUnderstanding Risk Factors Involved in Developing a Second Blood Clot.

Understanding Risk Factors Involved in Developing a Second Blood Clot.

Start: Oct 2002Est. completion: Mar 2016
N/AUnknown

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
23h ago
From $150K/yr

Associate Regional Clinical Consultant

Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday

Medical Affairs Sr Scientist- Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr

Labeling Operations Specialist

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday

Physician Program Director, Great North

Johnson & Johnson
Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)